Chandra Pharma Peer Comparison

BSE: 542934

₹40.00

₹0.00 (0.00%)

As on 19-Oct-2026IST

Market cap

₹30 Cr

Revenue (TTM)

₹116 Cr

P/E Ratio

9.9

P/B Ratio

0.9

Div. Yield

0 %

Edit

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	30	30,987	25,888	26,698	24,672
Revenue (₹ Cr)	116	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	3.05	414.00	-371.81	387.35	288.22
Net Margin (%)	2.55	11.23	-3.93	26.01	14.79
RoE (%)	9.76	8.38	-3.85	25.18	29.77
Price to Earnings	9.91	75.76	--	69.13	85.60
Price-To-Book	0.92	6.16	3.23	15.47	18.38

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	116.27	3,373.00	8,869.08	1,339.37	1,753.96
Total Income	119.63	3,510.00	9,111.51	1,380.95	1,762.66
Total Expenditure	112.49	2,747.00	7,976.59	858.97	1,354.69
EBITDA	3.78	626.00	892.49	480.40	399.26
Depreciation	1.03	227.00	831.24	35.99	45.26
EBIT	2.75	399.00	61.25	444.41	354.00
Interest	2.00	213.00	340.80	3.27	42.17
Other Income	3.35	137.00	242.43	41.59	8.70
Exceptional Items	--	-85.00	-196.14	--	--
Profit before Tax	4.11	238.00	-176.06	482.73	320.53
Provision for Tax	1.06	39.00	149.88	126.36	73.80
Profit after Tax	3.05	199.00	-325.94	356.37	246.74

Liabilities (₹ Cr)

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	33.13	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	--	341.00	--	57.19	0.00
Non-Current Liabilities	2.42	1,235.00	4,529.41	42.40	189.02
Current Liabilities	58.48	1,622.00	4,874.74	230.81	835.87
Total Liabilities	94.21	8,578.00	17,723.32	1,983.96	2,326.71

Assets (₹ Cr)

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	6.15	5,441.00	10,258.66	1,102.69	631.90
Current Assets	87.67	2,606.00	7,308.11	881.27	1,681.81
Total Assets	94.21	8,578.00	17,723.32	1,983.96	2,326.71
Total Debt*	16.51	2,125.00	5,495.48	26.49	259.37
Net Current Assets	29.19	984.00	2,433.37	650.46	845.94
Contingent Liabilities	--	768.26	95.72	17.25	19.09

Cashflow (₹ Cr)

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	9.24	390.00	1,652.60	292.17	205.05
Cash Flow from Investing Activities	-0.43	-241.00	-826.03	-265.94	-409.72
Cash from Financing Activities	-6.36	-54.00	-38.98	4.10	283.07
Net Cash Inflow / Outflow	2.45	95.00	787.59	30.33	78.39

Ratios

Profitability Ratios

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	12.24	6.79	1.24	32.42	29.22
ROE (%)	9.76	4.29	-4.04	24.08	27.84
ROA (%)	3.12	2.53	-1.98	20.17	13.11
EBIT Margin (%)	6.14	22.62	12.80	38.97	23.26
Net Margin (%)	2.55	5.67	-3.58	25.81	14.00
Cash Profit Margin (%)	3.51	10.98	4.80	29.29	7.71

Growth Ratios

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	30.93	11.99	-3.08	33.02	36.57
EBIT Growth (%)	78.64	67.69	-28.15	109.63	52.29
Net Profit Growth (%)	255.11	449.12	-457.66	122.15	83.64
EPS Growth (%)	255.11	553.20	-456.91	348.92	71.44
Book Value Growth (%)	11.43	13.47	0.33	26.03	144.31

Valuation Ratios

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	7.55	89.54	0.00	58.79	51.69
Price / Book Value	0.70	3.87	2.24	12.69	10.14
Dividend Yield (%)	0.00	0.00	0.00	0.10	0.19
EV/EBITDA	5.10	27.45	19.72	39.75	31.05
Market Cap (₹ Cr)	23.01	19,071.62	18,108.89	20,944.75	12,753.19

Solvency Ratios

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.50	0.43	0.68	0.02	0.21
Short term debt to equity ratio	0.40	0.09	0.09	0.02	0.05
Current Ratio	1.50	1.61	1.50	3.82	2.01
Quick Ratio	1.42	1.06	0.87	2.82	1.14
Interest Coverage	3.05	2.12	0.48	148.71	8.60

Operating Efficiency Ratios

	Chandra Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	46.97	17.43	24.33	27.07	29.00
Asset Turnover	1.19	0.49	0.64	0.76	2.01
Receivable days	142.15	58.75	78.20	88.98	40.13
Inventory Days	8.42	75.82	93.30	56.04	60.29
Payable days	79.66	186.21	226.14	99.95	232.47
Cash Conversion Cycle	70.91	-51.64	-54.64	45.07	-132.04

Annual
Quarterly